SuperAnalyst: the always-on AI agent for financial and strategic work.

SuperAnalyst monitors companies already in your CRM throughout the week, flagging meaningful news, looking for new names that fit your mandate—screened and flagged—, and automatically drafting outreach for the ones that make the cut.

Output: Prioritized pipeline view and outreach drafts.

SuperAnalyst audits what's there, what's missing, and which documents warrant attention first—then runs workflows to analyze revenue quality, cross reference seller assumptions against expert intelligence, and auto-generate an updated DRL in one session.

Output: First-pass IC deck, business overview, customer overview, management profile, key risks, and live diligence request list.

SuperAnalyst monitors the company between board meetings so you walk in knowing competitor moves, executive turnover, market shifts, all monitored continuously. Ahead of each meeting, SuperAnalyst hands you a pre-read, which scores management against last quarter's commitments and surfaces the questions you should be asking.

Output: Board scorecard, competitor and talent tracker, and follow-up questions.

SuperAnalyst assembles a list of strategic acquirers and PE sponsors that fit the target’s profile. Every name carries who's been called, who took the last meeting, and who passed and why.

Output: Ranked buyer universe, relationship history, sponsor profile, company brief, and outreach drafts.

SuperAnalyst puts together a teaser, process letter, and ranked buyer universe in a single session. Then a live deal workspace that tracks NDAs, working group lists, buyer activity, and diligence Q&A—updating automatically off incoming activity, with weekly process update memos drafted for your approval.

Output: Live NDA tracker, working group list, bidder log, diligence Q&A, weekly process update memo, and a bid comparison matrix.

SuperAnalyst gives you one workspace per covered name and continuously monitors M&A activity, executive changes, comp set trading, competitor moves, and expert sentiment. Ahead of any client meeting it drafts a one-page brief, outreach email, and proactive M&A ideas the MD can bring as conversation starters.

Output: Client brief, outreach draft, and M&A and strategic ideas.

SuperAnalyst names the players across your value chain, builds a disruption map scoring every use case against your value-chain stages, then lays out the strategic options—build, buy, or partner—against the capability gap that gates each move.

Output: Briefing packet with narrative doc, interactive HTML, and workbook, scored disruption map, value-pool migration view, roadmap, and build/buy/partner recommendation.

SuperAnalyst surfaces the 2–4 questions your sector is genuinely split on, works the sources methodically to gather both sides before concluding, and splits each debate by who's saying it—independent experts, the sell-side, and the companies themselves.

Output: Debate map, bull and bear cases, outcome mapping, necessary data points list, and forward-looking watchlist.

SuperAnalyst maps the whole field around you, classifying the universe by zone (acquirer, target, ecosystem), tiering every name by how live it is, surfacing the most actionable signals, and excluding what you already own—grounded in verifiable and cited evidence.

Output: Interactive M&A map, defensive picture, offensive shortlist, and cited rationale.

SuperAnalyst builds a player-level competitive scorecard from the ground up—a positioning matrix, a head-to-head grid scored on the dimensions that actually decide wins, and named player profiles with strengths, weaknesses, and direction of travel for each.

Output: Competitor scorecards, positioning matrix, head-to-head grid, and named player profiles.

SuperAnalyst continuously monitors clinical trial activity, FDA and EMA decisions, and label changes across your most relevant competitors, and triggers a synthesized, cited briefing the moment something material happens.

Output: Cited brief, trial or regulatory event readout, and competitive read-through.

SuperAnalyst runs the trial landscape scan, regulatory filing review, and payer/access analysis on the asset, then benchmarks peak sales scenarios against comparable approved drugs and stress-tests the bull case with a full clinical and competitive risk assessment.

Output: Asset underwriting brief, clinical history, competitive and regulatory risk assessment, and peak sales scenarios.